CLASS I Drug recall · Reported 9 Jun 2021 · FDA Enforcement Report
5% Bupivacaine Hydrochloride Injection, USP, 150 mg recalled by PFIZER
PFIZER is recalling 5% Bupivacaine Hydrochloride Injection, USP, 150 mg/ (5 mg/mL) Single-dose Teartop Vials (, distributed nationwide in the US. The recall was initiated on 3 May 2021 and the FDA has classified it as Class I.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0626-2021
- FDA event ID
- 87837
- Recalling firm
- PFIZER, Lake Forest, IL
- Manufacturer
- Hospira, Inc.
- Classification
- Class I
- Status
- Terminated
- Recall initiated
- 3 May 2021
- FDA classified
- 10 Jun 2021
- Reported
- 9 Jun 2021
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Packaging Defects
- Drug class
- Injectable & IV Drugs
Timeline
| 3 May 2021 | Recall initiated by company | |
| 9 Jun 2021 | Published in enforcement report | +37 days |
| 10 Jun 2021 | Classified by FDA | +1 day |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP
Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.
Product as listed by the FDA
0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19), packaged in 25 vials per tray (NDC 0409-1162-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.
Where it was distributed
Nationwide in the USA, Puerto Rico, and Guam
Questions about this recall
Is 5% Bupivacaine Hydrochloride Injection, USP, 150 mg/ (5 mg/mL) Single-dose Teartop Vials ( recalled?
Yes. PFIZER recalled 5% Bupivacaine Hydrochloride Injection, USP, 150 mg/ (5 mg/mL) Single-dose Teartop Vials ( on 3 May 2021. The recall is Class I and its status is Terminated. Recall number D-0626-2021.
Why was it recalled?
Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP
Which lots are affected?
Lot EG6023, Exp. 07/01/2022
Where was it sold?
Nationwide in the USA, Puerto Rico, and Guam
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class I mean?
Class I is the most serious FDA recall category: there is a reasonable probability that using the product will cause serious health consequences or death.
Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from PFIZER
All 126| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Vial Label: 4% Sodium Bicarbonate Injection, USP, 50mEq/ (1 mEq/mL) recalledSodium Bicarbonate | PFIZER | Sterility | Nationwide |
| Drug | CLASS II | Vial Label: Epinephrine Injection, USP, 1mg/ 1 mg/mL) recalled by PFIZER | PFIZER | Sterility | Nationwide |
| Drug | CLASS II | Levoxyl (levothyroxine sodium tablets, USP), 50 mcg recalled by PfizerLevoxyl | Pfizer | Potency & Assay | NY |
| Drug | CLASS II | Bicillin L-A (penicillin G benzathine injectable recalled by PfizerBicillin L-a | Pfizer | Particulate Matter | Nationwide |
| Drug | CLASS II | Bicillin L-A (penicllin G benzathine injectable suspension) per-vial recalledBicillin L-a | Pfizer | Particulate Matter | Nationwide |
Other Bupivacaine recalls
All 24| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Bupivacaine Hydrochloride 75% in 25% Dextrose Injection recalledBupivacaine Hydrochloride | Huons Co | Sterility | Nationwide |
| Drug | CLASS III | Zynrelef (bupivacaine and meloxicam), 400 mg bupivacaine recalledZynrelef | Heron Therapeutics | Packaging Defects | Nationwide |
| Drug | CLASS II | Bupivacaine HCl Injection, Single Dose Vial, 75%/7.5 mg/mL recalled | Mckesson Medical-Surgical Inc. Corporate Office | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Bupivacaine HCl Injection, single dose vial, Preservative Free recalledBupivacaine Hydrochloride | Mckesson Medical-Surgical Inc. Corporate Office | Manufacturing (CGMP) Deviations | Nationwide |
| Drug | CLASS II | Bupivacaine HCl Injection, single dose vial, 5%/5 mg/mL recalled | Mckesson Medical-Surgical Inc. Corporate Office | Manufacturing (CGMP) Deviations | Nationwide |